ORLANDO, Fla.--(Business Wire)--
Cardiovascular Sciences, Inc. (PINK SHEETS: CVSC) has been quite
busy, rapidly approaching a launch of its antioxidant, anti-aging cell
renewal formula and other select health related products. Initial
samples of the supplement have been delivered to the Company's
corporate offices and have exceeded the Company's expectations. The
supplement has also generated considerable interest from several
companies that market such products directly to physicians. Other
products complementary to the antioxidant have been delivered to the
fulfillment center.
A service agreement has been signed with United Fulfillment
Solutions, Inc. located in a large underground complex near St. Louis
and products are currently being delivered. Robert Lawrence, COO and
co-owner of UFSI, states, "We are excited that Cardiovascular Sciences
has chosen United Fulfillment as their order fulfillment provider.
Being located underground, we are able to maintain Cardiovascular's
products in a naturally climate controlled environment in the most
eco-friendly way available. Utilizing an underground fulfillment
center to support Cardiovascular Sciences' distribution needs results
in a savings of over 63% on energy usage and eliminates any risk that
other centers might experience in the event of the failure of their
climate control equipment."
Dr. Larry Hooper, CEO of Cardiovascular Sciences, Inc. explains,
"We are currently arranging and coordinating our new website with the
fulfillment center's software and that of various financial
institutions. We expect to beta test the ordering process within the
next few days and plan a full roll out the first week of August. Watch
for press releases as we accomplish these final stages before going
live."
About Cardiovascular Sciences
Cardiovascular Sciences, Inc. is an advanced medical device
company, with a primary focus of developing a novel technology
platform to address problems of post-surgical adhesions. Adhesions and
their complications are a significant problem worldwide for a broad
range of specialists, including general and cardiothoracic surgeons,
orthopedic, plastic, ophthalmologic and otolaryngology specialists to
name a few. In addition, the veterinary field has a tremendous need
for a product that can prevent similar problems in a variety of
animals. The Company's unique materials and processes promise a more
cost-effective and decidedly more efficient and capable means to deal
with a problem that has been so devastating to so many. Current
sponsored research at the UCF and previously at other institutions
indicate that the Company is on the right path and progressing well.
In addition to the anti-adhesion technology, the Company owns
technology in a variety of other areas, yielding a diversified
portfolio with projects in various stages of development.
Forward-looking statements in this release are made pursuant to
the Safe Harbor Provisions of the Private Securities Litigation Reform
Act of 1995. These forward-looking statements are subject to certain
risks and uncertainties, and actual results could differ from those
discussed. This material is information only and is not an offer or
solicitation to buy or sell the securities.
|
| # # # |
|
